Tumor-infiltrating lymphocytes and hepatocellular carcinoma: Pathology and clinical management

International Journal of Clinical Oncology

Volumn 15, Issue 6, 2010, Pages 552-558

  Shirabe, Ken ^a   Motomura, Takashi ^a   Muto, Jun ^a   Toshima, Takeo ^a   Matono, Rumi ^a   Mano, Yohei ^a   Takeishi, Kazuki ^a   Ijichi, Hideki ^a   Harada, Noboru ^a   Uchiyama, Hideaki ^a   Yoshizumi, Tomoharu ^a   Taketomi, Akinobu ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

CANCER TESTIS ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; COMPLEMENT COMPONENT C3B RECEPTOR; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; MACROPHAGE DERIVED CHEMOKINE; MELANOMA ANTIGEN; NY ESO 1 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD3+ CD56+ NATURAL KILLER T CELL; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ CD25- T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL EXPANSION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; EFFECTOR CELL; HISTOPATHOLOGY; HUMAN; IMMATURE DENDRITIC CELL; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MEMORY T LYMPHOCYTE; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; T-LYMPHOCYTES, REGULATORY;

EID: 78651073261     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0131-0     Document Type: Article

References (59)

1. S Scherlock 1994 Viruses and hepatocellular carcinoma Gut 35 828 832 10.1136/gut.35.6.828
2. K Shirabe T Kanematsu T Matsumata, et al. 1991 Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses Hepatology 14 802 805 1:STN:280:DyaK38%2FjvFGjsw%3D%3D 1657754 10.1002/hep.1840140510
3. Taketomi A, Fukuhara T, Morita K et al (2010) Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. [Epub ahead of print]
4. K Shirabe T Matsumata T Maeda, et al. 1995 A long-term surviving patient with hepatocellular carcinoma including lymphocytes infiltration: a clinicopathological study Hepatogastroenterology 42 996 1001 1:STN:280:DyaK283gs1KisA%3D%3D 8847059
5. Y Wada O Nakashima R Kutami, et al. 1998 Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration Hepatology 27 2 407 414 1:STN:280:DyaK1c7it1Cksg%3D%3D 9462638 10.1002/hep.510270214 (Pubitemid 28081054)
6. T Takayama T Sekine M Makuuchi, et al. 2000 Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet 356 9232 802 807 1:STN:280:DC%2BD3cvmvVSltg%3D%3D 11022927 10.1016/S0140-6736(00)02654-4
7. M Vivarelli R Bellusci A Cucchetti, et al. 2002 Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 1746 1751 12499891 10.1097/00007890-200212270-00017 (Pubitemid 36019329)
8. E Unitt A Marshall W Gelson, et al. 2006 Tumor lymphocyte infiltrate and recurrence of hepatocellular carcinoma following liver transplantation J Hepatol 45 178 181 10.1016/j.jhep.2005.12.027
9. S Eun YK Jeon JJ Jang 2010 Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation J Korean Med Sci 25 309 312 20119589 10.3346/jkms.2010.25.2.309
10. YL Pang HG Zhang JR Peng, et al. 2009 The immunosuppressive tumor microenviroment in hepatocellular carcinoma Cancer Immunol Immunother 58 877 886 1:CAS:528:DC%2BD1MXjvFOitLY%3D 18941744 10.1007/s00262-008-0603-5
11. MF Yuen RD Hughes MA Heneghan, et al. 2001 Expression of Fas antigen (CD95) in peripheral blood lymphocytes and liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma Cancer (Phila) 92 2136 2141 1:CAS:528:DC%2BD3MXot12rtbs%3D 10.1002/1097-0142(20011015)92:8<2136:: AID-CNCR1555>3.0.CO;2-J (Pubitemid 32973324)
12. Q Gao SJ Qiu J Zhou, et al. 2007 Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma J Clin Oncol 25 18 2586 2593 17577038 10.1200/JCO.2006.09.4565 (Pubitemid 47041232)
13. YW Li SJ Qiu J Fan, et al. 2009 Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection J Cancer Res Clin Oncol 135 439 449 18781326 10.1007/s00432-008-0469-0
14. E Unitt SM Rushbrook A Marshall, et al. 2005 Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells Hepatology 41 722 730 1:CAS:528:DC%2BD2MXjsV2ms7c%3D 15791620 10.1002/hep.20644 (Pubitemid 40462933)
15. + regulatory T cells affect the development and progression of hepatocellular carcinoma Clin Cancer Res 13 3 902 911 1:CAS:528:DC%2BD2sXhsVyrsL8%3D 17289884 10.1158/1078-0432.CCR-06-2363 (Pubitemid 46340366)
16. + regulatory T cells in patients with hepatocellular carcinoma EJSO (Eur J Surg Oncol) 34 173 179 1:STN:280: DC%2BD1c%2FltVOrug%3D%3D
17. J Zhou T Ding W Pan, et al. 2009 Increased intratumoral regulartory T cells are related to intratumoral macrophages and poor prognosis Int J Cancer 125 1640 1648 1:CAS:528:DC%2BD1MXpsVKmtrc%3D 19569243 10.1002/ijc.24556
18. Shen X, Li N, Li H et al (2010) Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage. J Cancer Res Clin Oncol 136:1745-1754
19. HX Yang S Yamagata T Ichida 2006 Increased of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma J Hepatol 45 254 262 1:CAS:528:DC%2BD28XmslylurY%3D 16600416 10.1016/j.jhep.2006.01.036
20. RK Gershon K Kondo 1991 Infectious immunological tolerance Immunology 21 903 914
21. E Yakirevich MB Resnick 2007 Regulatory T lymphocytes: pivotal components of host antitumor response J Clin Oncol 25 18 2506 2508 17577026 10.1200/JCO.2007.11.3191 (Pubitemid 47041221)
22. S Hori T Nomura S Sakaguchi 2003 Control of regulatory T cell development by the transcription factor FOXP3 Science 299 1057 1061 1:CAS:528: DC%2BD3sXhtFarsbw%3D 12522256 10.1126/science.1079490 (Pubitemid 36222930)
23. S Sakaguchi M Ono R Setoguchi, et al. 2006 FOXP3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease Immunol Rev 212 8 27 1:CAS:528:DC%2BD28XpvFegsbY%3D 16903903 10.1111/j.0105-2896.2006. 00427.x (Pubitemid 44116697)
24. EM Shevach 2002 CD4+CD25+ suppressor T cells: more questions than answers Nat Rev Immunol 2 389 400 1:CAS:528:DC%2BD38Xksl2murc%3D 12093005
25. S Sakaguchi 2004 Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses Annu Rev Immunol 22 531 562 1:CAS:528:DC%2BD2cXktlOgsLo%3D 15032588 10.1146/annurev. immunol.21.120601.141122 (Pubitemid 38680433)
26. + T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression on the tumor microenvironment Clin Cancer Res 13 15 4345 4354 1:CAS:528: DC%2BD2sXotlGqsLg%3D 17671115 10.1158/1078-0432.CCR-07-0472 (Pubitemid 47219698)
27. LW Collison CJ Workman TT Kuo, et al. 2007 The inhibitory cytokine IL-35 contributes to regulatory T cell functions Nature (Lond) 450 566 569 1:CAS:528:DC%2BD2sXhtlCrtbzI 10.1038/nature06306 (Pubitemid 350190247)
28. MA Gavin JP Rasmussen JD Fontenot, et al. 2007 FOXP3-denepdent programme of regulatory T-cell differentiation Nature (Lond) 445 771 775 1:CAS:528:DC%2BD2sXhslSqs74%3D 10.1038/nature05543 (Pubitemid 46279714)
29. Y Zheng SZ Josefowicz A Kas, et al. 2007 Genome-wide analysis of FOXP3 target genes in developing and mature regulatory T cells Nature (Lond) 445 936 940 1:CAS:528:DC%2BD2sXhvFGitLY%3D 10.1038/nature05563
30. K Nakamura A Kitani W Strober 2001 Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor beta J Exp Med 194 629 644 1:CAS:528:DC%2BD3MXms1KhsLo%3D 11535631 10.1084/jem.194.5.629 (Pubitemid 32844773)
31. K Wing Y Onishi P Prieto-Martin, et al. 2008 CTLA-4 control over FOXP3+ regulatory T cell function Science 322 271 275 1:CAS:528:DC%2BD1cXht1Slu7%2FJ 18845758 10.1126/science.1160062
32. M Ikeguchi Y Hirooka 2005 Interleukin-2 gene expression is a new prognostic marker in hepatocellular carcinoma Onkologie 28 255 259 1:CAS:528:DC%2BD2MXjvVSqtrY%3D 15867481 10.1159/000084695 (Pubitemid 40754671)
33. ZM Chen MJ O'Shaughnessy I Gramaglia, et al. 2003 IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function Blood 101 5076 5083 1:CAS:528:DC%2BD3sXkslCjtrc%3D 12609834 10.1182/blood-2002-09-2798
34. M Cao R Cabrera Y Xu, et al. 2007 Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+CD25+ regulatory T cells Lab Invest 87 582 590 1:CAS:528:DC%2BD2sXltlejsb4%3D 17372588
35. Q Gao XY Wang SJ Qiu, et al. 2009 Overexpression of PD-L1 significantly associated with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 3 971 979 1:CAS:528: DC%2BD1MXht1Ontr8%3D 19188168 10.1158/1078-0432.CCR-08-1608
36. DM Kuang Q Zhao C Peng, et al. 2009 Activated monocytes in peritumoral stroma foster immune privilege and disease progression through PD-L1 J Exp Med 206 6 1327 1337 1:CAS:528:DC%2BD1MXntFGmu7k%3D 19451266 10.1084/jem.20082173
37. TJ Curiel G Coukos L Zou, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 942 949 1:CAS:528:DC%2BD2cXntFSkt7g%3D 15322536 10.1038/nm1093 (Pubitemid 39273735)
38. S Gnjatics H Nishikawa AA Jungbluth, et al. 2006 NY-ESO-1: review of an immunogenic tumor antigen Adv Cancer Res 95 1 30 10.1016/S0065-230X(06)95001-5 (Pubitemid 44088423)
39. Shi F, Shi M, Zeng Z et al (2010) PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. Apr 19 [Epub ahead of print]
40. K Tahara M Mori N Sadanaga, et al. 1999 Expression of the MAGE gene family in human hepatocellular carcinoma Cancer (Phila) 85 6 1234 1240 1:STN:280:DyaK1M3gtlSisg%3D%3D 10.1002/(SICI)1097-0142(19990315)85:6<1234:: AID-CNCR4>3.0.CO;2-7 (Pubitemid 29125075)
41. MO Riener PJ Wild C Soll, et al. 2009 Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma Int J Cancer 124 352 357 1:CAS:528:DC%2BD1MXhvFaquw%3D%3D 18942708 10.1002/ijc.23966
42. G Bricard H Bouzourene O Martinet, et al. 2005 Naturally acquired MAGE A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma J Immunol 174 1709 1716 1:CAS:528:DC%2BD2MXlsFyktQ%3D%3D 15661935
43. AJ Gehring ZZ Ho AT Tan, et al. 2009 Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma Gastroenterology 137 682 690 1:CAS:528:DC%2BD1MXhtVKrtr%2FJ 19394336 10.1053/j.gastro.2009.04.045
44. H Nishikawa E Jager G Ritter, et al. 2005 CD4+ CD25+ regulatory T cells control of the induction of antigen-specific CD4+ helper T cell responses in cancer patients Blood 106 1008 1011 1:CAS:528:DC%2BD2MXntVSmsrw%3D 15840697 10.1182/blood-2005-02-0607 (Pubitemid 41076447)
45. NA Danke DM Koelle C Yee, et al. 2004 Autoactive T cells in healthy individuals J Immunol 172 5967 5972 1:CAS:528:DC%2BD2cXjs1OjtL0%3D 15128778
46. P Yu YX Fu 2006 Tumor-infiltrating T lymphocytes: friend or foes? Lab Invest 86 231 245 1:CAS:528:DC%2BD28XhsFSmurk%3D 16446705 10.1038/labinvest. 3700389 (Pubitemid 43276955)
47. M Zabala JJ Lasarte C Perret, et al. 2007 Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer J Hepatol 47 807 815 1:CAS:528:DC%2BD2sXht12ns7fM 17935823 10.1016/j.jhep.2007.07. 025 (Pubitemid 350051122)
48. F Huang PX Geng 2010 Chemokines and hepatocellular carcinoma World J Gastroenterol 16 15 1832 1836 1:CAS:528:DC%2BC3cXlsVyktbs%3D 20397259 10.3748/wjg.v16.i15.1832
49. I Tang HD Hu P Hu, et al. 2007 Gene therapy with CX3CL1/ Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma Gene Ther 14 1226 1234 1:CAS:528:DC%2BD2sXos1Cjtbs%3D 17597794 10.1038/sj.gt.3302959 (Pubitemid 47224554)
50. T Matsubara T Ono A Yamanori, et al. 2007 Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma J Surg Oncol 95 241 249 1:CAS:528: DC%2BD2sXjvVSjsrk%3D 17323338 10.1002/jso.20642
51. YQ Liu TR Poon J Hughes, et al. 2005 Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma World J Gastroentrol 11 2 164 170 1:CAS:528:DC%2BD2MXhs1eitLY%3D (Pubitemid 40125197)
52. KF Yoong SC Affiord R Jones, et al. 1999 Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by γ-interferon in lymphocyte recruitment to hepatocellular carcinoma Hepatology 30 100 111 1:CAS:528:DyaK1MXksVOqsL4%3D 10385645 10.1002/hep.510300147 (Pubitemid 29300575)
53. S Hirano Y Iwashita A Sasaki, et al. 2007 Increased mRNA expression of chemokines in hepatocellular carcinoma with tumor-infiltrating lymphocytes J Gastroenterol Hepatol 22 690 696 1:CAS:528:DC%2BD2sXmvVeju7g%3D 17444857
54. XY Cai Q Gao SJ Qui, et al. 2006 Dendritic cell infiltration and prognosis of human hepatocellular carcinoma J Cancer Res Clin Oncol 132 293 301 16421755 10.1007/s00432-006-0075-y
55. N Harada M Shimada S Okano, et al. 2004 IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressive mice J Immunol 173 6635 6644 1:CAS:528:DC%2BD2cXhtVShsLfF 15557154
56. H Kayashima T Toshima S Okano, et al. 2010 Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice J Immunol 185 698 708 1:CAS:528:DC%2BC3cXns1Cqt7s%3D 20498356 10.4049/jimmunol.0900187
57. X Cao K Leonard L Collins, et al. 2010 Interleukin 12 stimulates IFN-γ-mediated inhibition of tumor-induced regulatory T cell proliferation and enhances tumor clearance Cancer Res 69 22 8700 8709 10.1158/0008-5472.CAN- 09-1145
58. H Nishikawa S Sakaguchi 2010 Regulatory T cells in tumor immunity Int J Cancer 127 759 767 1:CAS:528:DC%2BC3cXnvFKru7k%3D 20518016
59. K Ko S Yamazaki K Nakamura, et al. 2005 Treatment of advanced tumors with agonistic anti-GITR m Ab and its effects on tumor-infiltrating FOXP3+ CD25+ CD4+ regulatory T cells J Exp Med 202 885 891 1:CAS:528:DC%2BD2MXhtVygt73I 16186187 10.1084/jem.20050940 (Pubitemid 41396888)